Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:IFRX 10 November 2025

InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx reported topline Phase 2a data for oral C5aR inhibitor INF904 in hidradenitis suppurativa and chronic spontaneous urticaria, showing no serious adverse events and clinically meaningful improvements in both conditions. The company ended Q3 2025 with €44.4 million in funds and projects a cash runway into 2027. A Phase 2b HS trial is planned for 2026.
10 November 2025
·

Stock Market Today

  • Albany International (AIN) Shares Enter Oversold Territory Amid Heavy Selling
    March 20, 2026, 5:53 PM EDT. Albany International Corp (AIN) shares hit an oversold level with a Relative Strength Index (RSI) reading of 25.1 on Friday, indicating strong recent selling pressure. The RSI, a momentum indicator on a 0-100 scale, signals a stock as oversold below 30, a potential sign that selling may be winding down. AIN's price touched a low of $48.27, close to its 52-week low of $47.65, compared to a high of $88.13. By contrast, the S&P 500 ETF (SPY) holds a moderate RSI of 47.3. Investors following Warren Buffett's guidance might view AIN's current RSI as an opportunity to buy while others are fearful.
Go toTop